Aurobindo Pharma Balance Sheet Health
Financial Health criteria checks 5/6
Aurobindo Pharma has a total shareholder equity of ₹308.8B and total debt of ₹80.9B, which brings its debt-to-equity ratio to 26.2%. Its total assets and total liabilities are ₹480.9B and ₹172.1B respectively. Aurobindo Pharma's EBIT is ₹49.8B making its interest coverage ratio 63.2. It has cash and short-term investments of ₹68.7B.
Key information
26.2%
Debt to equity ratio
₹80.91b
Debt
| Interest coverage ratio | 63.2x |
| Cash | ₹68.68b |
| Equity | ₹308.85b |
| Total liabilities | ₹172.09b |
| Total assets | ₹480.94b |
Recent financial health updates
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Recent updates
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors
Apr 10Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?
Jan 14Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet
Dec 27Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
Sep 07Is Aurobindo Pharma (NSE:AUROPHARMA) A Risky Investment?
Jun 14Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Trading At A 29% Discount?
May 21Aurobindo Pharma Limited's (NSE:AUROPHARMA) Intrinsic Value Is Potentially 93% Above Its Share Price
Feb 11Aurobindo Pharma (NSE:AUROPHARMA) Seems To Use Debt Quite Sensibly
Jan 09Is There An Opportunity With Aurobindo Pharma Limited's (NSE:AUROPHARMA) 50% Undervaluation?
Nov 02We Think Aurobindo Pharma (NSE:AUROPHARMA) Can Stay On Top Of Its Debt
Jun 20Financial Position Analysis
Short Term Liabilities: AUROPHARMA's short term assets (₹262.3B) exceed its short term liabilities (₹143.4B).
Long Term Liabilities: AUROPHARMA's short term assets (₹262.3B) exceed its long term liabilities (₹28.7B).
Debt to Equity History and Analysis
Debt Level: AUROPHARMA's net debt to equity ratio (4%) is considered satisfactory.
Reducing Debt: AUROPHARMA's debt to equity ratio has reduced from 37.2% to 26.2% over the past 5 years.
Debt Coverage: AUROPHARMA's debt is not well covered by operating cash flow (19.6%).
Interest Coverage: AUROPHARMA's interest payments on its debt are well covered by EBIT (63.2x coverage).